MediumEndocrinologyType 2 diabetes with cardiovascular diseaseca-mccqe1ca-rcpsc-im
A 67-year-old man with type 2 diabetes, prior non-ST elevation myocardial infarction, and an eGFR of 58 mL/min/1.73 m² is on metformin, ramipril, a high-intensity statin and low-dose acetylsalicylic acid. His HbA1c is 7.4%. According to Diabetes Canada, which additional therapy is most appropriate to reduce his cardiovascular risk?